n-3 fatty acids no benefit for high-risk cardio patients

n-3 fatty acids no benefit for high-risk cardio patients
For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

(HealthDay)—For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular mortality or morbidity, according to a study published in the May 9 issue of the New England Journal of Medicine.

Maria Carla Roncaglioni, Ph.D., from the Istituto di Ricerche Farmacologiche Mario Negri in Milan, and colleagues conducted a double-blind, placebo-controlled trial involving 12,513 patients with multiple or atherosclerotic vascular disease, but without myocardial infarction. Participants were randomized to receive 1 g daily n-3 fatty acids (6,244 participants) or placebo (olive oil; 6,269 participants).

With a median of five years of follow-up, the researchers found that the primary end point (cumulative rate of death, nonfatal , and nonfatal stroke) occurred in 11.8 percent of the cohort, 11.7 percent of whom had received n-3 fatty acids and 11.9 percent of whom had received placebo. Similar results were seen for all secondary end points.

"On the basis of the results, we conclude that there was no significant benefit of n-3 fatty acids in reducing the risk of death from cardiovascular causes or hospital admission for cardiovascular causes," the authors write.

The study was partially funded by Pfizer and Sigma Tau.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Fatty acids don't reduce atrial fibrillation recurrence

Dec 21, 2012

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Retinopathy severity linked to cardiovascular outcome

Jan 25, 2013

(HealthDay)—For individuals with type 2 diabetes, incident cardiovascular outcomes are determined not only by the severity of diabetic retinopathy but also by its progression, according to research published ...

Recommended for you

Vitamin K antagonist plus clopidogrel feasible for PCI

Sep 19, 2014

(HealthDay)—Vitamin K antagonists (VKA) combined with clopidogrel may be a better alternative to triple anticoagulant therapy in patients on long-term VKA undergoing percutaneous coronary intervention (PCI) ...

How pneumonia bacteria can compromise heart health

Sep 19, 2014

Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality—but how the heart is ...

An autoimmune response may contribute to hypertension

Sep 17, 2014

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

User comments